BACKGROUND: Dyskeratosis congenita (DC) is a progressive, multi-system, inherited disorder of telomere biology with high risks of morbidity and mortality from bone marrow failure, hematologic malignancy, solid tumors and pulmonary fibrosis. Hematopoietic stem cell transplantation (HSCT) can cure the bone marrow failure, but it does not eliminate the risks of other complications, for which life-long surveillance is required. Pulmonary fibrosis is a progressive and lethal complication of DC. CASE PRESENTATION: In this report, we describe a patient with DC who developed pulmonary fibrosis seven years after HSCT for severe aplastic anemia, and was successfully treated with bilateral lung transplantation. We also performed a systematic literature review to understand the burden of pulmonary disease in patients with DC who did or did not receive an HSCT. Including our patient, we identified 49 DC patients with pulmonary disease (12 after HSCT and 37 without HSCT), and 509 with no reported pulmonary complications. CONCLUSION: Our current case and literature review indicate that pulmonary morbidity is one of the major contributors to poor quality of life and reduced long-term survival in DC. We suggest that lung transplantation be considered for patients with DC who develop pulmonary fibrosis with no concurrent evidence of multi-organ failure.
BACKGROUND:Dyskeratosis congenita (DC) is a progressive, multi-system, inherited disorder of telomere biology with high risks of morbidity and mortality from bone marrow failure, hematologic malignancy, solid tumors and pulmonary fibrosis. Hematopoietic stem cell transplantation (HSCT) can cure the bone marrow failure, but it does not eliminate the risks of other complications, for which life-long surveillance is required. Pulmonary fibrosis is a progressive and lethal complication of DC. CASE PRESENTATION: In this report, we describe a patient with DC who developed pulmonary fibrosis seven years after HSCT for severe aplastic anemia, and was successfully treated with bilateral lung transplantation. We also performed a systematic literature review to understand the burden of pulmonary disease in patients with DC who did or did not receive an HSCT. Including our patient, we identified 49 DC patients with pulmonary disease (12 after HSCT and 37 without HSCT), and 509 with no reported pulmonary complications. CONCLUSION: Our current case and literature review indicate that pulmonary morbidity is one of the major contributors to poor quality of life and reduced long-term survival in DC. We suggest that lung transplantation be considered for patients with DC who develop pulmonary fibrosis with no concurrent evidence of multi-organ failure.
Authors: Lina Basel-Vanagaite; Inderjeet Dokal; Hannah Tamary; Abraham Avigdor; Ben Zion Garty; Alexander Volkov; Tom Vulliamy Journal: Haematologica Date: 2008-05-06 Impact factor: 9.941
Authors: Y Nakamura; M Iwata; M Ida; S Oda; E Takeuchi; K Asada; H Nakano; T Horiguchi; S Ooi; A Sato Journal: Nihon Kyobu Shikkan Gakkai Zasshi Date: 1997-09
Authors: Tom Vulliamy; Richard Beswick; Michael Kirwan; Anna Marrone; Martin Digweed; Amanda Walne; Inderjeet Dokal Journal: Proc Natl Acad Sci U S A Date: 2008-06-03 Impact factor: 11.205
Authors: S Imokawa; A Sato; M Toyoshima; A Yoshitomi; R Tamura; T Suda; H Suganuma; T Yagi; M Iwata; H Hayakawa Journal: Intern Med Date: 1994-04 Impact factor: 1.271
Authors: Andrew C Dietz; Sharon A Savage; Adrianna Vlachos; Parinda A Mehta; Dorine Bresters; Jakub Tolar; Carmem Bonfim; Jean Hugues Dalle; Josu de la Fuente; Roderick Skinner; Farid Boulad; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter Journal: Biol Blood Marrow Transplant Date: 2017-05-19 Impact factor: 5.742
Authors: Sofya Tokman; Jonathan P Singer; Megan S Devine; Glen P Westall; John-David Aubert; Michael Tamm; Gregory I Snell; Joyce S Lee; Hilary J Goldberg; Jasleen Kukreja; Jeffrey A Golden; Lorriana E Leard; Christine K Garcia; Steven R Hays Journal: J Heart Lung Transplant Date: 2015-05-11 Impact factor: 10.247
Authors: Andrew C Dietz; Parinda A Mehta; Adrianna Vlachos; Sharon A Savage; Dorine Bresters; Jakub Tolar; Farid Boulad; Jean Hugues Dalle; Carmem Bonfim; Josu de la Fuente; Christine N Duncan; K Scott Baker; Michael A Pulsipher; Jeffrey M Lipton; John E Wagner; Blanche P Alter Journal: Biol Blood Marrow Transplant Date: 2017-01-20 Impact factor: 5.742
Authors: Shahinaz M Gadalla; Carmem Sales-Bonfim; Jeanette Carreras; Blanche P Alter; Joseph H Antin; Mouhab Ayas; Prasad Bodhi; Jeffrey Davis; Stella M Davies; Eric Deconinck; H Joachim Deeg; Reggie E Duerst; Anders Fasth; Ardeshir Ghavamzadeh; Neelam Giri; Frederick D Goldman; E Anders Kolb; Robert Krance; Joanne Kurtzberg; Wing H Leung; Alok Srivastava; Reuven Or; Carol M Richman; Philip S Rosenberg; Jose Sanchez de Toledo Codina; Shalini Shenoy; Gerard Socié; Jakub Tolar; Kirsten M Williams; Mary Eapen; Sharon A Savage Journal: Biol Blood Marrow Transplant Date: 2013-06-08 Impact factor: 5.742